Nestlé in society Creating Shared Value and meeting our commitments 2015
nestle-csv-full-report-2015-en
nestle-csv-full-report-2015-en
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Nestlé</strong> <strong>in</strong> <strong>society</strong>:<br />
Creat<strong>in</strong>g <strong>Shared</strong> <strong>Value</strong><br />
Nutrition, health<br />
<strong>and</strong> wellness<br />
Rural development<br />
Water<br />
Environmental<br />
susta<strong>in</strong>ability<br />
Human rights<br />
<strong>and</strong> compliance<br />
Our<br />
people<br />
Customer health <strong>and</strong> safety G4-DMA<br />
Our R&D units Role (<strong>and</strong> research themes) <strong>2015</strong> collaborations<br />
(<strong>in</strong>ternal <strong>and</strong> external)<br />
Consumer benefits<br />
<strong>Nestlé</strong> Institute<br />
of Health<br />
Sciences (NIHS)<br />
Biomedical research <strong>in</strong>stitute<br />
specialis<strong>in</strong>g <strong>in</strong> metabolic health,<br />
gastro<strong>in</strong>test<strong>in</strong>al health, bra<strong>in</strong> health<br />
<strong>and</strong> age<strong>in</strong>g.<br />
• Signed research collaboration<br />
agreement with lead<strong>in</strong>g Swiss<br />
biopharmaceutical company AC<br />
Immune <strong>in</strong> September <strong>2015</strong>.<br />
• Began collaborative project with<br />
EpiGen to study sarcopenia at a<br />
molecular level.<br />
• The collaboration aims to<br />
develop a sensitive, m<strong>in</strong>imally<br />
<strong>in</strong>vasive procedure to map the<br />
early stages of Alzheimer’s<br />
disease by apply<strong>in</strong>g antibody<br />
technology provided by the<br />
NIHS.<br />
• Research will <strong>in</strong>dicate how<br />
<strong>in</strong>novative nutritional therapies<br />
can be applied to sarcopenia<br />
sufferers.<br />
Key bus<strong>in</strong>esses Role (<strong>and</strong> research themes) <strong>2015</strong> collaborations<br />
(<strong>in</strong>ternal <strong>and</strong> external)<br />
Consumer/patient benefits<br />
<strong>Nestlé</strong> Health<br />
Science (NHSc)<br />
A wholly owned <strong>Nestlé</strong> subsidiary<br />
engaged <strong>in</strong> advanc<strong>in</strong>g the role of<br />
nutritional therapy to change the<br />
c<strong>our</strong>se of health for consumers,<br />
patients <strong>and</strong> <strong>our</strong> partners <strong>in</strong><br />
healthcare.<br />
• Agreement signed with Lipid<br />
Therapeutics to deliver novel<br />
ulcerative colitis therapy.<br />
• Invested <strong>in</strong> Seres Therapeutics,<br />
to support phase III trials of<br />
SER-109 for the prevention of<br />
recurrent Clostridium difficile<br />
<strong>in</strong>fection (CDI). The US Food <strong>and</strong><br />
Drug Adm<strong>in</strong>istration (FDA)<br />
granted SER-109 orphan drug,<br />
as well as a breakthrough<br />
therapy designation <strong>in</strong> <strong>2015</strong>.<br />
<br />
www.serestheraputics.com<br />
In January 2016: NHSc <strong>and</strong><br />
Seres signed licens<strong>in</strong>g<br />
agreement (see Seres <strong>and</strong>/or<br />
NHSc website, newsroom).<br />
• Launched nutritional solutions<br />
such as Meritene® Mobilis (<strong>in</strong><br />
Europe) <strong>and</strong> Boost® nutritional<br />
dr<strong>in</strong>ks <strong>in</strong> compact sizes (<strong>in</strong> the<br />
United States) to meet the<br />
special needs of the age<strong>in</strong>g body.<br />
• Launched the Compat Ella®<br />
feed<strong>in</strong>g pump, which connects to<br />
patient data systems to ensure<br />
that feed<strong>in</strong>g rates are easily<br />
adjusted to patient needs, thereby<br />
improv<strong>in</strong>g cl<strong>in</strong>ical outcomes <strong>and</strong><br />
reduc<strong>in</strong>g care costs.<br />
• Launched CoMiSS®, an<br />
awareness tool to help primary<br />
healthcare professionals assess<br />
the likelihood of cow’s milk<br />
prote<strong>in</strong> allergy with 80%<br />
effectiveness.<br />
<strong>Nestlé</strong> Sk<strong>in</strong><br />
Health<br />
A wholly owned <strong>Nestlé</strong> subsidiary<br />
focus<strong>in</strong>g on meet<strong>in</strong>g the world’s<br />
<strong>in</strong>creas<strong>in</strong>g sk<strong>in</strong> health needs with a<br />
broad range of <strong>in</strong>novative <strong>and</strong><br />
scientifically proven products.<br />
• Announced plans to build new<br />
SHIELD centres <strong>in</strong> Shanghai,<br />
Ch<strong>in</strong>a, <strong>and</strong> São Paulo, Brazil.<br />
• This global <strong>in</strong>novation network<br />
aims to foster breakthroughs <strong>and</strong><br />
collaboration <strong>in</strong> sk<strong>in</strong> health<br />
through medical <strong>in</strong>vestigation,<br />
education <strong>and</strong> applications.<br />
<strong>Nestlé</strong> Nutrition<br />
Institute (NNI)<br />
Shares lead<strong>in</strong>g science-based<br />
nutrition <strong>in</strong>formation <strong>and</strong> education<br />
with healthcare professionals,<br />
scientists, <strong>and</strong> public health<br />
communities <strong>and</strong> stakeholders.<br />
• In <strong>2015</strong>, NNI supported<br />
13 <strong>in</strong>ternational congresses,<br />
hold<strong>in</strong>g satellite symposia at<br />
9 of them.<br />
• Works with healthcare<br />
professionals.<br />
<strong>Nestlé</strong> <strong>in</strong> <strong>society</strong> – Creat<strong>in</strong>g <strong>Shared</strong> <strong>Value</strong> <strong>and</strong> meet<strong>in</strong>g <strong>our</strong> <strong>commitments</strong> <strong>2015</strong> 51